Mike Mensinger bought $567k of BBNX
Chief Product Officer at Beta Bionics, Inc.. 33,350 shares at an average of $17.00, traded Jan 31, 2025, filed Feb 3, 2025.
Score components
- +15RoleOfficer
- +19Trade size$567k at market
- +10Relative to holdingsHoldings up 130%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -20.6%, 3m -48.7%, 6m -27.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-002819, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2025 | CConversion Common Stock | +15,107 | - | - | 15,107 | Feb 3, 2025 |
| Jan 31, 2025 | XIn-the-money exercise Common Stock | +10,575 | $0.02 | $212 | 25,682 | Feb 3, 2025 |
| Jan 31, 2025 | SOpen-market sale Common Stock | -13 | $17.00 | $221 | 25,669 | Feb 3, 2025 |
| Jan 31, 2025 | POpen-market purchase Common Stock | +33,350 | $17.00 | $567k | 59,019 | Feb 3, 2025 |
| Jan 31, 2025 | CConversion Series D Preferred Stockderivative | -15,107 | - | - | 0 | Feb 3, 2025 |
| Jan 31, 2025 | CConversion Class B Common Stock Warrant (right to buy)derivative | +10,575 | $0.00 | $0 | 10,575 | Feb 3, 2025 |
| Jan 31, 2025 | XIn-the-money exercise Class B Common Stock Warrant (right to buy)derivative | -10,575 | $0.00 | $0 | 0 | Feb 3, 2025 |
| Jan 31, 2025 | AGrant or award Employee Stock Option (right to buy)derivative | +236,553 | $0.00 | $0 | 236,553 | Feb 3, 2025 |
| Jan 31, 2025 | AGrant or award Employee Stock Option (right to buy)derivative | +110,278 | $0.00 | $0 | 110,278 | Feb 3, 2025 |
Related signals
Other insiders at Beta Bionics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $7,015 370 shares | -1% | |
| 26Weak | Beta Bionics, Inc. | Christy Jones director | $148k 6,430 shares | -25% | |
| 40Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $665k 35,994 shares | -29% | |
| 40Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $620k 30,779 shares | -35% | |
| 17Weak | Beta Bionics, Inc. | Mike Mensinger Chief Product Officer | $58k 2,650 shares | -1% | |
| 10Weak | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $12k 775 shares | -1% | |
| 41Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $681k 36,870 shares | -30% | |
| 30Weak | Beta Bionics, Inc. | Sean Saint President & CEO | $113k 5,641 shares | -1% | |
| 40Moderate | Beta Bionics, Inc. | Mark Hopman Chief Commercial Officer | $102k 5,327 shares | -4% | |
| 39Weak | Beta Bionics, Inc. | Mike Mensinger Chief Product Officer | $84k 4,375 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.